Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

About this update from Lexicon Pharmaceuticals, Inc.

Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groupsTHE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1 diabetes (T1D) and pilavapadin in diabetic peripheral neuropathic pain (DPNP) at the American Diabetes Association (ADA) 2026 Scientific Sessions, being held June 5-8 in New Orleans, Louisiana. “We look forward to engaging with the diabetes community at ADA 2026, as well as sharing additional data from clinical studies of our novel, orally administered investigational therapies for T1D and DPNP,” said Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer. “In particular, we are pleased to see continued evidence of the mechanistic benefits of SGLT1 and SGLT2 inhibition in people with T1D, reinforcing the potential of sotagliflozin ahead of a potential New Drug Application (NDA) resubmission in T1D, which is currently on track for mid-year 2026.” Presentation details:“Consistency of Glycemic Improvement with Sotagliflozin across Key Subgroups in Adults with Type 1 Diabetes: Pooled Analysis from inTandem Trials”Date: Sunday, June 7, 2026Time: 12:30 p.m. – 1:30 p.m. CESTLocation: Poster Hall (Halls D-E)Presenter: M. Belinda Hardin, PharmD, BCPS, US Medical Affairs, Lexicon Pharmaceuticals, Inc.“Renal Function Does Not Affect Pilavapadin Pharmacokinetics: Results from a Phase 1, Open-Label, Parallel-Group Study”Date: Sunday, June 7, 2026Time: 12:30 p.m. – 1:30 p.m. CESTLocation: Poster Hall (Halls D-E)Presenter: Rodica Pop-Busui M.D., Ph.D, Oregon Health & Science UniversityAbout SotagliflozinDiscovered using Lexicon’s unique approach to gene science, sotagliflozin is an oral inhibitor of two proteins responsible for glucose regulation known as sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). SGLT2 is responsible for glucose and sodium reabsorption by the kidney and SGLT1 is responsible for glucose and sodium absorption in the gastrointestinal tract. Sotagliflozin has been studied in multiple patient populations encompassing heart failure, diabetes, and chronic kidney disease in clinical studies involving approximately 20,000 patients. Sotagliflozin is also curre...

View stock analysis, news, and events for Lexicon Pharmaceuticals, Inc.